CompletedPhase 4NCT01511003

A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)

Studying NON RARE IN EUROPE: Rheumatoid arthritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Astellas Pharma Inc
Principal Investigator
Use Central Contact
Astellas Pharma Inc
Intervention
Tacrolimus(drug)
Enrollment
128 enrolled
Eligibility
20-75 years · All sexes
Timeline
20112015

Study locations (4)

Collaborators

Astellas Pharma Korea, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01511003 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Rheumatoid arthritis

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Rheumatoid arthritis

← Back to all trials